Gene Editing Market Research Report- Global Forecast to 2030

Gene Editing Market Research Report: Information By Methods (Crispr, Talen, Zfn, Antisense Technology And Others), By Applications (Plant Genetic Engineering, Animal Genetic Engineering, Gene Therapy, Microorganisms Genetic Engineering), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) ‚Äď Market Forecast Till 2030

ID: MRFR/LS/0236-HCR | 80 Pages | Published By Rahul Gotadki on March 2023         

Gene Editing Market Speak to Analyst Request a Free Sample

Global Gene Editing Market Overview

The gene editing market value is expected to grow at a CAGR (Compound Annual Growth Rate) of about 14.7% to reach USD 19.4 billion over the forecast 2022-2030.Significant progress in drug discovery research, an increase in research projects and the growth of the biotechnology industry are just a few market drivers driving the gene editing market. 
Gene Editing Market Overview
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Gene Editing Market Trends

  • Increased financing for genetic research will boost gene editing market growth.

Additionally, a rise in gene editing research and development (R&D) activities is fueling gene editing market revenue expansion. For example, on June 2, 2022, CRISPR-Combo, a method developed by scientists at the University of Maryland's College of Agriculture and Natural Resources, enables the editing of several genes in plants while concurrently changing the expression of other genes. With the help of the National Institute of Food and Agriculture of the United States Department of Agriculture (USDA), this new technique will enable genetic engineering combinations to improve crop breeding and functioning.

Governments worldwide have recently made large expenditures in the science of genomics, which has greatly influenced the advancement of novel genome editing technologies. Additionally, the availability of government financing has made it possible for government and university institutions to do extensive research on genome engineering. For instance, the Ministry of Innovation, Science, and Industry (Science) announced in March 2020 that Genome Canada would receive USD 15 million to fund 11 genomic research initiatives in health, agriculture, and the environment. Provincial governments, companies, and research partners will also spend USD 29.7 million to assist these research programs. The initiatives cover ovarian and cervical cancer research. There has been a tremendous increase in genomics research initiatives due to large government funding. Thus, this factor is driving the gene editing market CAGR.

The United States Food and Drug Administration granted permission to researchers at the University of California (U.C.), San Francisco, UC Berkeley, and UC Los Angeles in March 2021 to jointly begin an early phase, first-in-human clinical trial of a gene correction therapy in sickle cell disease patients using the patient's blood-forming stem cells.

Similarly, Merck and Takara Bio USA, Inc. struck a licensing deal in October 2020. Through this arrangement, Takara has been granted a license from Merck to use its CRISPR technology to create vectors and other cutting-edge products to assist CRISPR-based research and cell engineering services, notably for stem cells. Thus, it is anticipated that this aspect will accelerate Gene Editing market revenue globally.

Gene Editing Market Segment Insights

Gene Editing Method Insights

The Gene Editing market segmentation, based on Method, includes Crispr, Talen, Zfn, Antisense Technology and Others. The Crispr segment held the majority share in 2022 in the Gene Editing market data. It is mainly because of its expanded use in agriculture, biotechnology, and healthcare. CRISPR/Cas9 research is being conducted to discover treatments for life-threatening conditions, including the human immunodeficiency virus and Huntington's disease (HIV). The growth of the mutant protein was decreased by roughly 90% in mice models using CRISPR/Cas9, according to a study, which suggests that a mutant protein is what causes Huntington's disease. Studies show that CRISPR/Cas9 can successfully remove the receptors that cause viral infections. CRISPR techniques are being used in several hundred tests and research worldwide; thus, it is anticipated that this technology will continue to rule the gene editing market.

Figure 1: Gene Editing Market, by Method, 2022 & 2030 (USD Billion) 
Gene Editing Market, by Method, 2022 & 2030
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Gene Editing Application Insights

Based on application, the Gene Editing market segmentation includes Plant Genetic Engineering, Animal Genetic Engineering, Gene Therapy, and Microorganisms Genetic Engineering. The Gene Therapy segment dominated the market growth in 2022 and is projected to be the faster-growing segment during the forecast period, 2022-2030. DNA and cell technologies are combined using this Method for cell lines. The development of rational genetic engineering to enhance biotherapeutic proteins has been accelerated by the publication of the genomic sequences of multiple Chinese Hamster Ovary (CHO) cell lines. Thanks to CRISPR technology, scientists working with CHO have understood the molecular mechanisms underlying high-level protein production and pertinent Product Quality Attributes (PQAs). Changes in glycosylation patterns can enhance the bioactivity and quality of biological products, and N-linked glycosylation plays a critical role in the efficacy of therapeutic proteins.

Gene Editing Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The Asia Pacific Gene Editing market accounted for USD 3.38 billion in 2022, with a share of around 45.80%, and is expected to exhibit a significant CAGR growth during the study period. The highest revenue share came from the Japanese gene editing market, which benefited from considerable research on gene editing technology. For instance, Sanatech Seed debuted the first directly ingested tomato with genome editing in Japan in 2021. According to Japanese ministries, the genome-edited tomato will not be subject to regulation as a genetically modified product. Red Sicilian Sanatech Seed developed a high GABA tomato using CRISPR-Cas9 gene editing. Tomatoes contain significant amounts of gamma-aminobutyric acid (GABA), an amino acid that aids in relaxing and lowering blood pressure. Further, the China Gene Editing market held the largest market share, and the India Gene Editing market was the fastest-growing market in the region.

Further, the major countries studied in the market report are The U.S., Canada, Germany, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Due to increased spending on R&D and the development of life science research, the Europe Gene Editing market held a consistent revenue share in 2021. Additionally, the growing use of genomics in medicine has significantly influenced the expansion of the gene editing sector in Europe. The highest revenue share came from the U.K. market. One of the main factors fueling this region's market revenue development is introducing new rules for gene editing technologies. For instance, the U.K. Government declared on January 20, 2022, that scientists and engineers working on plants in England would have better access to genetic technologies, such as gene editing. Moreover, the UK Gene Editing market held the largest market share, and the Germany Gene Editing market was the fastest-growing market in the region.

North America gene editing market held a significant share in the market. The agriculture and healthcare infrastructures, which quickly absorb new technology, aid in the region's ability to maintain its dominating position. Six thousand six hundred registered biotechnology businesses and more than 2,000 pharmaceutical companies are located in the U.S., according to data. Canada is home to more than 50 renowned pharmaceutical corporations and more than 1,000 registered biotechnology businesses. The number of pharmaceutical and biotechnology businesses in the area will keep increasing due to policies that generally support company growth, enhancing regional growth.

Gene Editing Key Market Players & Competitive Insights

Major industry companies are investing a lot of money in R&D to expand their product offerings, which will spur further market expansion for the Gene Editing industry. With significant industry changes, including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other organizations, market developments are also undertaking various strategic activities to expand their presence. To grow and remain in a market that is becoming more and more competitive, Gene Editing industry competitors must provide affordable products.

Manufacturing locally to cut operational costs is one of the producers' main business methods in the Gene Editing industry to benefit customers and increase the market sector. The Gene Editing industry has recently given medicine some of the most important advantages. The Gene Editing market major player such as GenScript USA Inc. (U.S.), Horizon Discovery Group plc (U.K.), Integrated DNA TechnologiesInc. (U.S.), Lonza Group Ltd. (Switzerland), New England BiolabsInc. (U.S.), OriGene TechnologiesInc. (U.S.) Company.

With operations throughout 18 nations, Eli Lilly and Firm is an American pharmaceutical company with its main headquarters in Indianapolis, Indiana. Approximately 125 nations sell their products. The business was established in 1876 and is named after Colonel Eli Lilly, an American war veteran and pharmacist. With a preliminary focus on Duchenne muscular dystrophy (DMD) and two other undisclosed gene targets, Eli Lilly and Company and Precision BioSciences, Inc. announced a research partnership and exclusive license agreement to use Precision's proprietary ARCUS genome editing platform for the investigation and development of potential in vivo treatments for genetic disorders on November 20, 2020. A variety of therapeutic editing is made possible by the distinctive, exclusive, and adaptable ARCUS genome editing platform. Its features include specificity, versatility in efficient edits (knock-in, knock-out, and repair), and small size. This approach is based on the naturally occurring genome-editing enzyme I-CreI, a homing endonuclease with tunable potency and selectivity.

A division of E. Merck KG is the science and technology firm Merck KGaA (Merck). Merck KGaA licensed its proprietary CRISPR-Cas9 technology to create next-generation therapies to Cellecta in October 2021. As a result, researchers and scientists have been able to enhance therapies for hereditary blood problems, malignancies, and ophthalmological conditions.

Key Companies in the Gene Editing market include

GenScript USA Inc. (U.S.)

Horizon Discovery Group plc (U.K.)

Integrated DNA TechnologiesInc. (U.S.)

Lonza Group Ltd. (Switzerland)

New England BiolabsInc. (U.S.)

OriGene TechnologiesInc. (U.S.)

Gene Editing Industry Developments

  • May 2019:With the addition of Brammer Bio's expertise in the production of vectors for genes and cell treatments, Thermo Fisher Scientific purchased Brammer Bio to expand its market presence globally.

  • June 2021:An agreement for the development of induced pluripotent stem cells for the treatment of retinal illnesses was announced by Alpine BioTherapeutics Corporation and Allele Biotechnology. This tactic helped the business create a cutting-edge product range.

  • May 2020:With MaxCyte, Caribou Science negotiated a commercial and clinical license deal. The goal of the arrangement was to get exclusive rights to use the ExPERT platform and MaxCyte's flow electroporation technology. The gene-edited allogeneic T-cell treatment initiatives at Caribou were progressed by this tactic, which also increased their business connections in the gene editing industry.

Gene Editing Market Segmentation

Gene Editing Product Methods Outlook (USD billion, 2018-2030)


  • Talen

  • Zfn

  • Antisense Technology

Gene Editing Applications Outlook (USD billion, 2018-2030)

  • Plant Genetic Engineering

  • Animal Genetic Engineering

  • Gene Therapy

  • Microorganisms Genetic Engineering

Gene Editing Regional Outlook (USD Billion, 2018-2030)

  • North America

  • US

  • Canada

  • Europe

  • Germany

  • France

  • UK

  • Italy

  • Spain

  • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Australia

    • Rest of Asia-Pacific

  • Rest of the World

    • Middle East

    • Africa

    • Latin America

Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 19.4 billion
  CAGR   14.7% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Methods, Applications and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GenScript USA Inc. (U.S.), Horizon Discovery Group plc (U.K.), Integrated DNA Technologies, Inc. (U.S.), Lonza Group Ltd. (Switzerland), New England Biolabs, Inc. (U.S.), OriGene Technologies, Inc. (U.S.), Sangamo Biosciences, Inc. (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Transposagen Biopharmaceuticals, Inc. (U.S.)
  Key Market Opportunities   Increasing government support to boost biotechnology sector for better treatment of diseases
  Key Market Drivers ·  Huge development in drug discovery research ·  Increase in number of research studies, development of biotechnology sector

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Gene editing is a bimolecular method for targeted modification of DNA, including the genetic materials of plants, animals, and humans. In gene editing, a DNA strand is inserted, deleted, or replaced in the genome of an organism to treat particular diseases or other specific conditions.

The key players in the gene editing market are GenScript USA Inc. (U.S.), Horizon Discovery Group plc (U.K.), Integrated DNA Technologies Inc. (U.S.), Lonza Group Ltd. (Switzerland), and New England BiolabsInc. (U.S.), OriGene TechnologiesInc. (U.S.)

Increasing awareness about the role of genetics in the development of a number of chronic diseases is the major driver for the Gene Editing Market.

Gene therapy has the largest share of the global gene editing market.

CRISPR holds the largest share in the Global Gene Editing Market.